OEL Fastrac Catalog

Please note, this OEL/ADE monograph also applies to dextropropoxyphene hydrochloride (CAS RN 1639-60-7), dextropropoxyphene napsylate (CAS RN 26570-10-5), dextropropoxyphene napsylate anhydrous (CAS RN 17140-78-2), and dextropropoxyphene pamoate (CAS RN Not Available). Dextropropoxyphene is an opioid narcotic analgesic that is structurally related to methadone. The drug is often referred to as the general form “propoxyphene”; however, only the dextro-isomer (dextropropoxyphene or d-propoxyphene) has any analgesic effect. The levo-isomer appears to exhibit a very limited antitussive effect. Dextropropoxyphene is a pain reliever prescribed for the treatment of mild to moderate pain. The European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) have recommended that all dextropropoxyphene-containing preparations be no longer available in the Europe (EU) and United States of America (USA) based on safety reasons, although such preparations may be on the market in other countries.

Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.

Why do you need this OEL Fastrac monograph?

OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:

• The numerical OEL and control band assignment needed to determine the level of required engineering controls and personal protective equipment
• A listing of all cited references utilized in the derivation of the OEL and ADE
• An expert review and discussion with respect to the critical endpoints of concern, the rationale for the choice of endpoints, and dose that is to be used in the derivation of the ADE (PDE), as required by the EMA's Guideline on setting health-based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities

Benefits of OEL Fastrac monographs

• Fully documented. Over 20 pages in length, with calculations and cited references.
• Save time! Unsurpassed delivery with instant download.
• Save money. Similar documents cost 5-12 times as much.
• Stay current. Automatic notification of revisions.

How to order

To order an OEL/ADE monograph for Dextropropoxyphene, just click the ADD TO CART button.

HBEL

If you're wondering about HBEL, we have something for you.